share_log

中國生物製藥：自願公告 - 「鹽酸安羅替尼膠囊」、「TQB2916（CD40激動劑）」、「FHND6091（蛋白酶體抑制劑）」共6項研究數據在2024 AACR公佈

SINO BIOPHARM: VOLUNTARY ANNOUNCEMENT - DATA OF 6 STUDIES REGARDING "ANLOTINIB HYDROCHLORIDE CAPSULES", "TQB2916 (CD40 AGONIST)" AND "FHND6091 (PROTEASOME INHIBITOR)" WERE PRESENTED AT 2024 AACR

香港交易所 ·  Apr 10 08:02
Summary by Moomoo AI
中國生物製藥有限公司宣佈，旗下三款創新藥「鹽酸安羅替尼膠囊」、「TQB2916（CD40激動劑）」及「FHND6091（蛋白酶體抑制劑）」在2024年美國癌症協會年會（AACR）上公佈了6項研究成果。其中，「鹽酸安羅替尼膠囊」在消化道腫瘤和小細胞肺癌的臨床研究顯示，聯合化療一線治療可顯著提高療效；「TQB2916」在晚期惡性腫瘤的I期臨床研究中，表現出良好的藥代動力學特性和免疫激活作用；「FHND6091」則在膽管癌治療中展現出潛在的療效。這些研究結果為公司的創新藥物開發帶來正面影響，有望為癌症患者提供新的治療選擇。公司董事會於2024年4月10日發布此消息。
中國生物製藥有限公司宣佈，旗下三款創新藥「鹽酸安羅替尼膠囊」、「TQB2916（CD40激動劑）」及「FHND6091（蛋白酶體抑制劑）」在2024年美國癌症協會年會（AACR）上公佈了6項研究成果。其中，「鹽酸安羅替尼膠囊」在消化道腫瘤和小細胞肺癌的臨床研究顯示，聯合化療一線治療可顯著提高療效；「TQB2916」在晚期惡性腫瘤的I期臨床研究中，表現出良好的藥代動力學特性和免疫激活作用；「FHND6091」則在膽管癌治療中展現出潛在的療效。這些研究結果為公司的創新藥物開發帶來正面影響，有望為癌症患者提供新的治療選擇。公司董事會於2024年4月10日發布此消息。
CHINA BIOPHARMACEUTICAL CO., LTD. ANNOUNCED THE RESULTS OF 6 STUDIES AT THE AMERICAN CANCER SOCIETY ANNUAL MEETING (AACR) IN 2024 AT THE AMERICAN CANCER SOCIETY ANNUAL MEETING (AACR), AND “FHND6091 (PROTEIN ENZYME INHIBITOR)” UNDER ITS THREE INNOVATIVE DRUGS, “ALOTINIC HYDROCHLORIDE CAPSULE”, “TQB2916 (CD40 STIMULANT)” AND “FHND6091 (PROTEINASE INHIBITOR).” Among them, “Alotinic hydrochloride capsule” demonstrated significant efficacy in clinical studies in gastrointestinal tumors and small cell lung cancer; “TQB2916” demonstrated good pharmacokinetic properties and immunostimulating effects in Phase I clinical studies of late-stage malignant tumors; “FHND6091 has shown potential efficacy in the treatment of bile duct cancer. These results have a positive impact on the company's development of innovative drugs, which are expected to provide new treatment options for cancer patients. The Board of Directors issued this announcement on April 10, 2024.
CHINA BIOPHARMACEUTICAL CO., LTD. ANNOUNCED THE RESULTS OF 6 STUDIES AT THE AMERICAN CANCER SOCIETY ANNUAL MEETING (AACR) IN 2024 AT THE AMERICAN CANCER SOCIETY ANNUAL MEETING (AACR), AND “FHND6091 (PROTEIN ENZYME INHIBITOR)” UNDER ITS THREE INNOVATIVE DRUGS, “ALOTINIC HYDROCHLORIDE CAPSULE”, “TQB2916 (CD40 STIMULANT)” AND “FHND6091 (PROTEINASE INHIBITOR).” Among them, “Alotinic hydrochloride capsule” demonstrated significant efficacy in clinical studies in gastrointestinal tumors and small cell lung cancer; “TQB2916” demonstrated good pharmacokinetic properties and immunostimulating effects in Phase I clinical studies of late-stage malignant tumors; “FHND6091 has shown potential efficacy in the treatment of bile duct cancer. These results have a positive impact on the company's development of innovative drugs, which are expected to provide new treatment options for cancer patients. The Board of Directors issued this announcement on April 10, 2024.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more